Heterogeneity and pleiotropy test in the examined associations and weak instrument statistics between lipid phenotypes mediated by lipid-lowering drug targets (HMGCR, PCSK9, and NPC1L1) and cystic kidney disease and polycystic kidney disease. This evidence concerns the gene NPC1L1 and polycystic kidney disease.